OGS Appoints Donald W. DeGolyer to Main Board as President of Global Therapeutics

    OXFORD, UK, March 5 /PRNewswire-FirstCall/ --
 Oxford GlycoSciences Plc (LSE: OGS, Nasdaq:   OGSI) announced today that it has
 appointed Don DeGolyer to the OGS Board of Directors as President of Global
 Therapeutics with immediate effect.
     Don joined OGS in September 2001 to lead the commercialisation of OGS'
 drug products, including its lead compound Vevesca (OGT 918), an oral
 treatment for type 1 Gaucher disease, which is currently undergoing regulatory
 review.  Prior to joining OGS, Don spent 16 years with Pfizer and Johnson &
 Johnson where he was Vice President of Marketing and Sales.
     Commenting on the appointment, Kirk Raab, Chairman of OGS said, "Don has
 already made a substantial contribution to OGS through his leadership of
 Global Therapeutics and I am delighted to welcome him to the main Board."
 
     Notes to Editors
     OGS has developed a patented technology platform in the emerging field of
 proteomics, the comprehensive study of proteins, integrating proteomics with
 genomics to create an innovative drug discovery platform.  OGS' proteomics
 collaborations with major pharmaceutical and biotechnology companies include
 Bayer, Pioneer Hi-Bred/DuPont, Medarex/GenMab, GlaxoSmithKline, NeoGenesis and
 Pfizer.  OGS has technology development collaborations with Applera, Cambridge
 Antibody Technology, Packard BioScience and the Institute for Systems Biology.
 OGS has also entered into a joint venture, Confirmant Limited, to develop the
 Protein Atlas of the Human Genome(TM).
     OGS has drug research discovery programmes in central nervous system,
 cancer, infectious disease and glycosphingolipid (GSL) storage disorders.  OGS
 has had submissions to regulatory authorities accepted for review in both
 Europe and the US for its development compound, Vevesca (OGT 918), for the
 treatment of type 1 Gaucher disease.
 
     This release contains forward-looking statements, such as the commercial
 potential and success of OGS' collaborations and drug candidates.  Factors
 that could cause actual results to vary significantly from those expressed or
 implied by these and other forward-looking statements include the success of
 OGS' research and development strategies, the validity of its technologies and
 intellectual property position and strategies, the medical conclusions on
 which Vevesca (OGT 918) is based and uncertainties related to the regulatory
 process. Vevesca (OGT 918) is an investigational drug and has not received
 approval for marketing in any country.
 
     For further information please contact:
      Oxford GlycoSciences Plc
      Michael Kranda, Chief Executive Officer
      Dr Stephen Parker, Chief Financial Officer
      Tel: +44 (0) 1235 208000
      WorldWide Web: www.ogs.com
 
      UK: Financial Dynamics
      Melanie Toyne Sewell/Sarah Mehanna
      Tel: +44 (0) 20 7831 3113
           +44 (0) 20 7269 7236
 
      USA: Feinstein Kean
      Michelle Linn/Michael Lawson
      Tel: +1 (617) 761 6765
           +1 (617) 577 8110
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X78237165
 
 

SOURCE  Oxford GlycoSciences Plc